- Report
- October 2024
- 193 Pages
Global
From €3924EUR$3,939USD£3,315GBP
- Report
- August 2024
- 136 Pages
Global
From €2987EUR$2,999USD£2,524GBP
- Report
- January 2025
- 372 Pages
Global
From €5429EUR$5,450USD£4,587GBP
- Report
- May 2024
- 100 Pages
Africa
From €1992EUR$2,000USD£1,683GBP
- Report
- April 2024
- 80 Pages
United States
From €1494EUR$1,500USD£1,262GBP
- Report
- January 2025
- 546 Pages
Global
From €6968EUR$6,995USD£5,887GBP
- Report
- October 2024
- 188 Pages
Global
From €3924EUR$3,939USD£3,315GBP
- Report
- January 2025
- 89 Pages
Global
From €5578EUR$5,600USD£4,713GBP
- Report
- January 2025
- 158 Pages
Global
From €5429EUR$5,450USD£4,587GBP
- Report
- January 2025
- 183 Pages
Global
From €4483EUR$4,500USD£3,787GBP
- Report
- September 2024
- 187 Pages
Global
From €4483EUR$4,500USD£3,787GBP
- Report
- July 2024
- 150 Pages
Global
From €3736EUR$3,750USD£3,156GBP
- Report
- July 2024
- 158 Pages
Global
From €3387EUR$3,400USD£2,861GBP
€4234EUR$4,250USD£3,577GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4981EUR$5,000USD£4,208GBP
- Report
- August 2023
- 1500 Pages
Global
From €8716EUR$8,750USD£7,364GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4981EUR$5,000USD£4,208GBP
- Report
- June 2022
- 55 Pages
India
From €4981EUR$5,000USD£4,208GBP
- Report
- January 2022
- 42 Pages
Global
From €3736EUR$3,750USD£3,156GBP
- Report
- September 2021
- 144 Pages
China
From €3985EUR$4,000USD£3,366GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3985EUR$4,000USD£3,366GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more